What is the preferred clinical management of hyperglycemia related to alpelisib?
Answer from: Medical Oncologist at Academic Institution
The side effects common to several pi3k/Akt/mtor pathway inhibitors include hyperglycemia and rash.Compared to patients treated with everolimus, hyperglycemia is more common with alpelisib. The incidence of all-grade hyperglycemia was 14% in BOLERO-2, with grade 3 or 4 hyper...
Comments
Medical Oncologist at University of Wisconsin School of Medicine and Public Health Interestingly, this arose today in clinic. Cycle 1...
Interestingly, this arose today in clinic. Cycle 1...